This article is more than 5 years old. Information may no longer be current.

China approves patents for Rockwell’s Triferic

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Rockwell Medical Inc. said the State Intellectual Property Office of the People's Republic of China (SIPO) has accepted patent claims relating to ESA sparing, compositions and use for Triferic.

The claims allowed in the patent application, entitled “Methods of Treating Iron Deficiency with Soluble Ferric Pyrophosphate” include composition of matter and use of soluble ferric pyrophosphate to reduce ESA usage using hemodialysis solution with the specific dose. The patent provides protection through February 2034.

“We are thrilled to receive this important patent and the valuable IP protection it provides in the Chinese market,” said Robert L. Chioini, chairman and CEO of Rockwell. “We view China as a key strategic dialysis market that we anticipate may become the world’s largest over the next several years."